Skip to main content
SpringerLink
Log in

The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma

  • Conference paper
Minimal Residual Disease in Melanoma

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 158))

Abstract

Cutaneous melanoma is characterized by a high propensity for metastasis. Currently, surgical intervention remains the mainstay of therapy. This approach has proven most beneficial when the diagnosis is of early stage primary lesions. Likewise, patients undergoing resection for a solitary site of metastasis have shown a survival advantage. Identification of metastatic disease depends predominantly on radiographic techniques requiring the presence of significant tumor burdens for successful imaging. However, at that time, the role of surgery and/or biochemotherapy may be of limited value. Techniques to identify minimal disease states may permit more accurate assessment of prognosis. The detection of occult tumor cells by RT-PCR in the blood, lymph nodes, and bone marrow of melanoma patients provides one such approach to monitor tumor progression. Single-marker RT-PCR has been used as one such approach but is noted to have limitations in sensitivity and specificity based on the heterogeneity of tumor marker expression among tumors as well as within an individual tumor lesion or among multiple lesions in individual patients. We employed a multimarker reverse transcriptase polymerase chain reaction assay that demonstrates improved sensitivity over a single-marker approach. Currently, the consequences of detecting systemic subclinical metastasis remain unknown pending longer-term follow-up. The detection of occult melanoma cells using molecular techniques in conjunction with known clinicopathologic prognostic factors may provide a novel and efficient approach in monitoring tumor progression and further identify high-risk patients diagnosed early in the disease course.

The work reported here was supported in part by NIH PO1 grants CA 12582 and CA 1038, Roy E. Coats Research Foundation, Los Angeles, CA, USA

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hsueh EC, Gupta RK, Glass EC et al (1998) Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J AM Coll Surg 187:191–197

    Article  PubMed  CAS  Google Scholar 

  2. Eton O, Legha SS, Moon TE et al (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103–1111

    PubMed  CAS  Google Scholar 

  3. Liotta L, Stetler-Stevenson G (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51:5054–5059

    Google Scholar 

  4. Goldblatt SA, Nadel FM (1965) Cancer cells in the circulating blood: a critical review II. Acta Cytol 9:6–20

    PubMed  CAS  Google Scholar 

  5. Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer (Supp) 80:1529–1537

    Article  PubMed  CAS  Google Scholar 

  6. Dhillon AP, Rode J, Leathem A (1982) Neurone specific enolase: an aid to the diagnosis of melanoma and neuroblastoma. Histopathology 6:81–92

    Article  PubMed  CAS  Google Scholar 

  7. Horikoshi T, Ito S, Wakamatsu K et al (1994) Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73:629–636

    Article  PubMed  CAS  Google Scholar 

  8. Letellier S, Gamier JP, Spy J et al (1997) Determination of the L-DOPA/L-tyrosine ratio in human plasma by high-performance liquid chromatography. Usefulness as a marker in metastatic melanoma. J Chrom B Biomed Sci Appl 696:9–17

    Article  CAS  Google Scholar 

  9. Hasegawa M, Takata M, Hatta N et al (1997) Simultaneous measurement of serum 5-Scysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 7:243–251

    Article  PubMed  CAS  Google Scholar 

  10. Wibe E, Paus E, Aamdal S (1990) Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Cancer Lett 52:29–31

    Article  PubMed  CAS  Google Scholar 

  11. Buzaid AC, Sandler AB, Hayden CL et al (1994) Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol 17:430–431

    Article  PubMed  CAS  Google Scholar 

  12. Hoon DSB, Irie RF, Cochran AJ (1988) Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cellular Immun 111:410–419

    Article  CAS  Google Scholar 

  13. Schutter EM, Visser JJ, van Kamp GJ et al (1992) The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature. Tumour Biol 13:121–132

    Article  PubMed  CAS  Google Scholar 

  14. Miliotes G, Lyman GH, Cruse CW et al (1996) Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3:558–563

    Article  PubMed  CAS  Google Scholar 

  15. Guo HB, Stoffel-Wagner B, Bierwirth T et al (1995) Clinical sinificance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31 A:1898–1902

    Article  Google Scholar 

  16. Schultz ES, Diepgen TL, Driesch P (1997) Clinical and prognostic relevance of serum S100B protein in malignant melanoma. Br J Derm 138:426–430

    Article  Google Scholar 

  17. Hauschild A, Engel G, Brenner W et al (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–344

    Article  PubMed  CAS  Google Scholar 

  18. Gaynor R, Irie R, Morton D et al (1980) S100 protein is present in cultured human malignant melanomas. Nature 286:400–401

    Article  PubMed  CAS  Google Scholar 

  19. Gaynor R, Herschman HR, Irie R et al (1981) S100 protein: a marker for human malignant melanomas? Lancet 1:869–871

    Article  PubMed  CAS  Google Scholar 

  20. Cochran AJ, Lu HF, Li PX et al (1993) S100 protein remains a practical marker for melanocytic and other tumors. Melanoma Res 3:325–330

    Article  PubMed  CAS  Google Scholar 

  21. Nakajima T, Watanabe S, Sato Y et al (1982) Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 50:912–918

    Article  PubMed  CAS  Google Scholar 

  22. Fagnart OC, Sindic CJ, Laterre C (1988) Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34:1387–1391

    PubMed  CAS  Google Scholar 

  23. Seregni E, Massaron S, Martinetti A et al (1998) S100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 5:601–604

    PubMed  CAS  Google Scholar 

  24. Buer J, Probst M, Franzke A et al (1997) Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 75:1373–1376

    Article  PubMed  CAS  Google Scholar 

  25. Braun S, Muller M, Hepp F et al (1998) Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status (correspondence). J Natl Cancer Inst 90:1099–1100

    Article  PubMed  CAS  Google Scholar 

  26. Bonfrer JMG, Korse CM, Nieweg OE et al (1998) The luminescence immuoassay S-100: A sensitive test to measure circulating 5–100B: its prognostic value in malignant melanoma. Br J Cancer 77:2210–2214

    Article  PubMed  CAS  Google Scholar 

  27. Smith B, Selby P, Southgate J et al (1991) Detection of malanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. The Lancet 338:1227–1229

    Article  CAS  Google Scholar 

  28. Brossart P, Keilholz U, Willhauck M et al (1993) Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Derm 101:887–889

    Article  PubMed  CAS  Google Scholar 

  29. Battayani Z, Grob JJ, Zerri L et al (1995) Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Derm 131:443–447

    Article  PubMed  CAS  Google Scholar 

  30. Foss AJE, Guille MJ, Occleston NL et al (1995) The detection of melanoma cells in perpheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 72:155–159

    Article  PubMed  CAS  Google Scholar 

  31. Kunter U, Buer J, Probst M et al (1996) Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 88:590–594

    Article  PubMed  CAS  Google Scholar 

  32. Pittman K, Burchill S, Smith B, et al (1996) Reverse transcriptase polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 7:297–301

    PubMed  CAS  Google Scholar 

  33. Mellado B, Colomer D, Castel T et al (1996) Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol 14:2091–2097

    PubMed  CAS  Google Scholar 

  34. Glaser R, Rass K, Seiter S et al (1997) Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J Clin Oncol 15:2818–2825

    PubMed  CAS  Google Scholar 

  35. Reinhold U, Ludtke-Handjery H-C, Schnautz S et al (1997) The analysis of tyrosinasespecific mRNA in blood samples of melanoma patients by reverse transcriptase polymerase chain reaction is not a useful test for metastatic tumor progression. J Invest Derm 108:166–169

    Article  PubMed  CAS  Google Scholar 

  36. Mellado B, Gutierrez L, Castel T et al (1999) Prognostic significance of the detection of circulating malignant cells by reverse transcriptase polymerase chain reaction in longterm clinically disease-free melanoma patients. Clin Cancer Res 5:1843–1848

    PubMed  CAS  Google Scholar 

  37. Curry BJ, Myers K, Hersey P (1998) Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 16:1760–1769

    PubMed  CAS  Google Scholar 

  38. Bosserhoff A-K, Kaufmann M, Kaluza B et al (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153

    PubMed  CAS  Google Scholar 

  39. Muhlbauer M, Langenbach N, Stolz W et al (1999) Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transscription-polymerase chain reaction. Clin Cancer Res 5:1099–1105

    PubMed  CAS  Google Scholar 

  40. Hoon DSB, Wang Y, Dale PS et al (1995) Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13:2109–2116

    PubMed  CAS  Google Scholar 

  41. Sarantou T, Chi DD, Garrison DA et al (1997) Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371–1376

    PubMed  CAS  Google Scholar 

  42. Hoon DSB, Garrison D, Chi DDJ et al (1996) Molecular detection of tumor-associated antigens shared by human melanomas and gliomas. EASES J 10:1414

    Google Scholar 

  43. Chi DDJ, Merchant RE, Rand R et al (1997) Molecular detection of tumorassociated antigens shared by human cuntaneous melanomas and gliomas. Am J Path 150:2143–2152

    PubMed  CAS  Google Scholar 

  44. Kuo CT, Bostick PJ, Irie RF et al (1998) Assessment of messenger RNA of βl->4-N-acetylgalactosaminyltransferase as a molecular marker for metastatic melanoma. Clin Cancer Res 4:411–418

    PubMed  CAS  Google Scholar 

  45. Shivers SC, Wang X, Li W et al (1998) Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 280:1410–1415

    Article  PubMed  CAS  Google Scholar 

  46. Morton DL, Wen DR, Wong JH et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399

    PubMed  CAS  Google Scholar 

  47. Bostick PJ, Morton DL, Turner RR et al (in press) Prognostic significance of occult metastasis detected by sentinel lymphadenectomy and RT-PCR in clinical stage I melanoma patients. J Clin Oncol

    Google Scholar 

  48. Zippelius P, Kufer P, Honold G et al (1997) Limitations of reverse-transcriptase polymerase chain reaction analysis for detection of micrometastasic epithelial cancer cells in bone marrow. J Clin Oncol 15:2701–2708

    PubMed  CAS  Google Scholar 

  49. Putz E, Witter K, Offner S et al (1999) Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastasis. Cancer Res 59:241–248

    PubMed  CAS  Google Scholar 

  50. Ghossein R, Coit D, Brennan M et al (1998) Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 4:419–428

    PubMed  CAS  Google Scholar 

  51. Zetter BR (1990) The cellular basis of site-specific tumor metastasis. N Engl J Med 322:605–612

    Article  PubMed  CAS  Google Scholar 

  52. Hoon DSB, Bostick P, Kuo C et al (2000) Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 60:2253–2257

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA

    B. Taback, D. L. Morton, S. J. O’Day, D.-H. Nguyen, T. Nakayama & D. S. B. Hoon

Authors
  1. B. Taback
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. L. Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. J. O’Day
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D.-H. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. S. B. Hoon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätskliniken des Saarlandes Haut- und Poliklinik, 66421, Homburg/Saar, Germany

    Uwe Reinhold  & Wolfgang Tilgen  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Taback, B., Morton, D.L., O’Day, S.J., Nguyen, DH., Nakayama, T., Hoon, D.S.B. (2001). The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma. In: Reinhold, U., Tilgen, W. (eds) Minimal Residual Disease in Melanoma. Recent Results in Cancer Research, vol 158. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59537-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59537-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64015-5

  • Online ISBN: 978-3-642-59537-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation